sees q3 non-gaap earnings per share $2.25 to $2,35 excluding items.
q2 non-gaap earnings per share $2.60.
sees fy 2021 non-gaap earnings per share $10.50 to $ 10.70.
sees q3 sales up 7% to 9% in constant currency.
sees fy 2021 diluted earnings per share to be approximately 62 million.
q3 gaap earnings per share $2.69.
sees q3 sales up 8% to 10%.
qtrly net sales rose 6% on a constant currency basis.
q2 non-gaap earnings per share $2.60.
qtrly revenue increased 31% as reported and 27% on a constant currency basis, driven by continued strength in pharma and industrial end markets.
q2 sales rose 27 percent to $682 million.
q2 gross margin was 58.9% versus refinitiv ibes estimate of 58.8%.
sees fy sales up 14% to 17%.
q2 average share count was 62.2 million, an increase of approximately 1 percent from q2 of 2020.
sees fy 2021 constant currency sales growth of 13% to 15%.
sees fy gross margin about 58% to 58%.
